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Abstract
Objective. Renal involvement is common in systemic sclerosis (scleroderma; SSc) and includes
chronic kidney disease (CKD). We have performed analysis of urinary proteins to gain insight into local
molecular pathology of CKD in SSc and identify candidate markers for use in clinical trials.
Methods. To evaluate urinary proteins that might specifically reflect SSc-related CKD, patients were
recruited with confirmed SSc and stratified for the presence or absence of CKD. Controls included
patients with CKD and no SSc, in addition to healthy volunteers. Candidate markers were measured in
serum and urine by multiplex immunoassay testing for IL6, IL18, TNF-a, monocyte chemoattractant
protein 1 (MCP1), monocyte chemoattractant protein 3 (MCP3), VEGF and the soluble adhesion mole-
cules vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1).
Results. One hundred and two subjects were examined, including patients with SSc with no evidence
of CKD (n¼ 40), SSc with CKD (n¼ 39), non-SSc CKD (n¼ 11) and healthy volunteers (n¼ 12). Urinary
levels of IL6, MCP1, TNF-a, MCP3, IL18 and ICAM-1 were elevated in SSc patients compared with
healthy controls. The most significant differences were for MCP1 and ICAM-1 (both P< 0.0001), and
these analytes also showed the most significant differences between groups overall (P¼ 0.003 for
MCP1 and P< 0.0001 for ICAM-1). These markers showed a trend (MCP1, P¼ 0.0868) or a significant
difference (ICAM-1, P¼ 0.0134) between SSc–CKD and SSc with normal renal function.
Conclusion. Urinary levels of candidate molecular markers appear to reflect SSc–CKD more than
serum markers. MCP1 and ICAM-1 are promising molecular markers for SSc–CKD and might be po-
tential biomarkers of SSc renal involvement. This might be explored in future prospective analyses.
Key words: renal, biomarker, scleroderma, systemic sclerosis, chemokine, adhesion molecule
Key messages
. Elevated inflammatory proteins in serum of SSc patients reflect disease biology at multiple sites.
. In SSc, urinary proteins can provide insight into local disease mechanisms in chronic kidney disease.
. This study identifies two candidate renal biomarkers, urinary ICAM-1 and MCP1, that might be specific for SSc.
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Introduction
Systemic sclerosis (scleroderma; SSc) is a multi-system
disease with high mortality owing to the involvement of
vital organs, including the heart, lungs, gut and the renal
tract [1]. Renal complications can be serious, and in the
past, accelerated phase hypertension and acute kidney
injury attributable to scleroderma renal crisis (SRC) was
the most frequent cause of death in SSc [2]. The overall
outcome of SRC has improved owing to routine use of
angiotensin-converting enzyme inhibitors in managing
the acute episode of SRC and better supportive care for
the longer-term consequences [3]. The pathobiology of
SRC is incompletely understood, although recent ge-
netic and histological analyses identify potential molecu-
lar mechanisms relevant to susceptibility and
pathogenesis [4].
Although recovery from the acute kidney injury of SRC
is often excellent, SRC remains an important mechanism
leading to chronic kidney disease (CKD) in SSc. In addi-
tion, CKD occurs in a large proportion of SSc patients
because of systemic vasculopathy, fibrosis and other
mechanisms, such as overlap CTD, including SLE and
vasculitis. Other pathologies, such as interstitial nephritis
or drug toxicity, can also contribute to CKD in SSc.
Previous studies of sequential unselected patients sug-
gested that CKD is present in 50% of SSc cases [5].
Although often presenting as mild renal impairment that
is not of immediate clinical importance, CKD has implica-
tions for long-term renal and patient outcomes and is a
major determinant of the long-term outcome after SRC.
Creatinine-derived measures of glomerular filtration
rate (GFR) deteriorate only once there is significant pa-
renchymal abnormality in the kidney; therefore, there is
a general need for more sensitive markers of disease
activity in CKD, including the context of SSc. Such tests
might also help to discriminate SSc from non-SSc-
related processes in the kidney in order that manage-
ment could be more appropriate. In addition, new
markers could help in distinguishing clinically important
or progressive CKD from more stable cases. Easily mea-
sured biomarkers could be applied to outcome assess-
ment in clinical trials or practice and might provide early
indicators of therapeutic response that could predict fu-
ture clinical benefit.
There have been many recent studies exploring po-
tential biomarkers in SSc, and these have focused on
examination of skin biopsies or peripheral blood, includ-
ing cell-based approaches such as gene expression, in
addition to methods examining serum, plasma or micro-
particles [6, 7]. Composite serum markers, such as the
enhanced liver fibrosis test, have been correlated with
skin and lung fibrosis in cross-sectional studies [8].
Discovery approaches have identified new serum
markers and components of innate immunity using more
advanced methods, such as high-resolution protein
analysis and mass cytometry [6, 9, 10].
In addition to blood, urine offers a highly relevant and
accessible substrate to explore candidate biomarkers of
SSc-related CKD (SSc–CKD). Urine potentially has sig-
nificant advantages over serum or plasma as a fluid for
renal biomarker investigation. It is produced in direct
contact with the epithelial surface of the organ of inter-
est, meaning that relevant proteins expressed in renal
injury might be shed directly into the urine. For this rea-
son, urine has been described as a ‘fluid biopsy’ of the
kidney and renal tract [11]. Furthermore, urine can be
obtained non-invasively from subjects, typically in larger
volumes than are available for serum or plasma. In the
present study, we have, for the first time, used multiplex
technology to measure simultaneously proteins that are
plausible markers of SSc–CKD and have included con-
trol samples with non-SSc CKD, healthy controls and
cases of SSc with no evidence of CKD.
In the present study, we have analysed candidate uri-
nary proteins in SSc–CKD and compared them with se-
rum levels of these analytes. To determine which urinary
proteins might be relevant specifically to SSc–CKD by
reflecting local molecular pathology, we have compared
levels in urine, after correction for urinary creatinine, for
SSc, SSc–CKD and non-SSc–CKD patients. In this way,
we expected to differentiate potential markers of SSc
pathobiology in the kidney that might be useful in clinical
trials and also provide insight into the likely mechanisms
of CKD that occur in SSc and might impact on clinical
outcomes, such as susceptibility to, or recovery after
acute kidney injury occurring in the context of sclero-
derma renal crisis (SRC).
Methods
Selection of candidate serum and urine markers
Candidate markers of renal involvement to measure in
urine and serum of patients with SSc and controls were
defined from previous literature and current concepts of
the molecular pathology of SSc and other related multi-
system autoimmune rheumatic diseases. The aim was
to have a selection of proteins that would help to iden-
tify inflammatory, fibrotic and vasculopathic processes
in the renal parenchyma that would add to conventional
assessment of renal abnormalities, such as serum creat-
inine and GFR. The following markers were selected for
measurement.
IL6 is a likely pathogenic mediator of inflammation
and connective tissue dysfunction in SSc. Its expression
in urine has been correlated with renal disease in several
contexts, including the autoimmune CTD SLE [12].
IL18 has been demonstrated to be a mediator of
ischaemic damage to the renal tubule in mice [13], and
urine concentrations have been validated as a marker of
acute kidney injury in humans [14].
TNF-a is a putative mediator of endothelial damage in
SSc [15]. Serum and urinary concentrations have been
demonstrated to be raised in other forms of nephropa-
thy [16, 17].
VEGF is overexpressed in tissue biopsies and sera
from patients with SSc [18]. It is expressed in urine in








ap/article/5/1/rkaa083/6067415 by guest on 24 June 2021
disease states, and concentrations are independent of
the serum concentration [19].
Monocyte chemoattractant proteins 1 (MCP1 or
CCL2) and 3 (MCP3 or CCL7) have been described as
pathogenic fibroblast activators in SSc [20], and high se-
rum levels have been associated with organ-specific
disease activity [21]. Urine concentrations of MCP1 have
shown promise as a marker of renal involvement in SLE
and diabetic kidney disease [22–24].
Soluble ICAM-1 has been associated with disease se-
verity in SSc in serum and is considered to be a marker
of activated endothelium, epithelial cells and fibroblasts
[25]. It is expressed and shed in greater quantities in
SSc fibroblasts than control fibroblasts [26].
Soluble VCAM-1 has been associated with fibroblast
activation and epithelial-to-mesenchymal transition and
is a marker of immune cell activation and endothelial
cell activation. It is elevated in SRC in other series and
has been shown to be increased markedly in the serum
in some cases of SRC [25, 27]. Urinary levels have not
been examined previously in SSc.
Study design and participants
This study was approved by the Royal Free Research and
Development team and by the Newcastle and North
Tyneside Research Ethics Committee. All individuals pro-
vided informed consent for their participation, according
to the guidance set out by the research ethics committee.
The study cohort of 79 adult patients attending the
scleroderma clinic at the Royal Free Hospital was recruited
prospectively. All had definite SSc classified by 2013 ACR/
EULAR classification criteria [28]. Kidney function was eval-
uated using the modification of diet in renal disease esti-
mated glomerular filtration rate (MDRD eGFR) equation
[29]. This reflects standard reporting in our centre over the
past decade, and we expect that this formula will not differ
significantly from the Chronic Kidney Disease
Epidemiology Collaboration (CDK-EPI) formula that is also
used in other laboratories [30]. Patients with eGFR of
<60 ml/min/1.73 m2 or <90 ml/min with persistent urinary
blood or protein on dipstick were categorized as having
CKD, consistent with CKD stages 2–5 in the 2002 guide-
lines by the Kidney Disease Outcomes Quality Initiative
(KDOQI) [31]. By including SSc samples without CKD and
non-SSc CKD groups, we hoped that we would identify uri-
nary proteins that are specifically elevated in SSc–CKD
and which might reflect the molecular pathology of SSc in
CKD. Of the cohort, 40 patients with SSc were classified as
no CKD and 39 patients with SSc and CKD. As controls, 11
patients with CKD attributable to other causes (without
nephrotic-range proteinuria) were recruited from the gen-
eral nephrology clinic at the Royal Free Hospital. A further
12 healthy controls, with no diagnosis of SSc and normal
renal function, were also included.
Clinical data
In addition to demographic data (age, sex and ethnicity),
the medical history was recorded. For the SSc groups,
this included disease-specific organ complications, skin
subgroup (limited or diffuse) and the disease-specific
ANA. These data are summarized in Table 1.
Sample collection and management
From each individual recruited to the study, concurrent
urine and blood samples were collected. Clotted blood
and fresh mid-stream urine were centrifuged at 600 g at
4C, for 10 min, within 1 h of collection. After centrifuge
and serum separation, the serum and urine were divided
into aliquots and frozen at 80C.
Additional blood and urine samples were sent to the
Royal Free Hospital laboratories for routine clinical bio-
chemistry analysis, including serum creatinine, eGFR
and urinary albumin:creatinine ratio.
Multiplex analysis of serum and urine
Multiplex immunoassay for all eight analytes was per-
formed according to the manufacturer’s protocol
(Luminex Corporation, Austin, TX, USA). Standards sup-
plied with the assay kits, urine and serum samples were
analysed in duplicate wells. Urine biomarker concentra-
tions (in picograms per millilitre) were expressed as a ra-
tio to the urine creatinine concentration (in micromoles
per litre) to compensate for diurnal variations in the wa-
ter concentration of spot urine samples.
Statistical analysis
Four patient groups (SSc–CKD, SSc–no CKD, non-SSc
CKD and control) were compared for each candidate
biomarker. The difference between these groups was
assessed using the Kruskal–Wallis test. The SSc–CKD
group was also compared individually with each of the
other three groups using the Mann–Whitney U-test.
Correlation between eGFR and biomarker concentra-
tions was assessed using Pearson’s coefficient. All sta-
tistical tests were performed using GraphPad Prism
v.8.2.1 for Windows (GraphPad Software, La Jolla, CA,
USA).
Results
Overall results for the eight proteins analysed in this
study are detailed in Table 2 for serum and Table 3 for
urine. Individual plots for each serum protein are shown
in Fig. 1 and urine levels, after correction for urinary cre-
atinine concentration, in Fig. 2.
Seven of the candidate proteins were detectable in
the serum of patients with SSc–CKD and control groups.
MCP3 was detectable in the serum of only one subject
in the SSc–CKD group and none of the subjects in the
three control groups and is therefore of limited value for
further analysis. All eight candidate proteins were de-
tectable in urine by our method in subjects in all four
groups.
Two of the candidate urinary proteins (MCP1 and
ICAM-1) showed a higher degree of discrimination be-
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assess whether differences in GFR among our patients
would account for the difference in urine concentrations.
Relationship of candidate urinary markers MCP1
and ICAM-1 with renal function
The detectable concentration of low molecular weight
proteins in the urine is inextricably related to the blood
concentration of the same proteins and the volume of
blood filtered by the kidneys (i.e. the GFR). To investi-
gate the relationship between kidney function and con-
centrations of MCP1 and ICAM-1 in urine, urinary
concentrations were plotted against MDRD eGFR and
serum creatinine (from which the eGFR is derived).
These data are included in Fig. 3.
For the ICAM-1:creatinine ratio, there was a significant
negative correlation with eGFR (R ¼ 0.42, P¼ 0.0001)
and positive correlation with serum creatinine (R¼0.46,
P¼0.00002). The correlation for urinary MCP1:creatinine
with eGFR followed the same trend but was weaker (R
¼ 0.32, P¼ 0.0046). Examination of the dot plots for
each marker suggested that the relationship between
eGFR and ICAM-1:creatinine was more consistent and
robust than that for urinary MCP1. This suggested for
MCP1 that raised urinary levels might reflect local path-
ogenic processes rather than simply lower GFR, consis-
tent with widespread expression of MCP1 in SSc renal
biopsy specimens [30].
Discussion
This project is part of an overarching attempt to look for
local sites of disease-associated protein expression in a
systemic condition. In this way, we delineated potential
markers or mediators of molecular pathology in SSc-
associated renal disease. By comparing the findings for
SSc-related CKD with non-SSc-related CKD we were
able to assess molecular markers that reflected SSc, and
by focusing on SSc cases with CKD we reasoned that
this would reflect the overall disease process of SSc that
was relevant to a target organ, the kidney, in the context
of a multi-system disease. Thus, we harnessed the
strengths of this approach by including non-CKD SSc
controls, in which there was unlikely to be relevant renal
pathology, and non-SSc CKD, where the chronic renal
impairment was likely to have arisen by non-SSc mecha-
nisms. This study design favoured identification of spe-
cific markers of SSc–CKD and offered potential insight
into SSc pathobiology more generally by providing confi-
dence that the urinary proteins were associated with local
functionally relevant pathology of SSc.
In this study, we show that urinary levels of proteins
implicated in SSc pathogenesis have potential as bio-
markers for detection and surveillance of renal involve-
ment in this multi-system disease. Based on previous
studies of serum markers in SSc and emerging data on
urinary analytes in other renal diseases, we selected
eight candidates to assess in our well-characterized co-
hort of SSc patients and relevant controls.
Although many of the proteins were elevated in SSc
serum compared with controls, this appears to have
reflected disease occurring in multiple organs, be-
cause there was no clear difference between serum
levels in SSc–CKD and SSc–no CKD. In fact, for half of
the proteins the average level was higher in SSc–no
CKD, suggesting that disease outside the kidneys had
most influence on serum levels. Although not statisti-
cally significant, it is notable that VCAM-1 levels on av-
erage were higher in SSc–CKD, because the levels
have been shown previously to be increased in SRC
[26, 27].
Our findings confirm previous studies of cytokines
and adhesion molecules in SSc patients. These have
demonstrated a correlation of the MCP1 level with skin
sclerosis and with the change in lung function in clinical
trials [32]. However, most of these studies have focused
on serum levels, and this is a challenge for a multicom-
partment disease, such as SSc, where elevated levels
can reflect disease in the skin, lung, kidney or other vas-
cular structures. This might explain why it has been diffi-
cult to identify strong correlations with lung fibrosis or
pulmonary arterial hypertension in general cohorts [21].











Age, years 57 (2.1) 63 (1.7) – 58 (5.1) 34 (2.4)
eGFR, ml/min/1.73 m2 80 (1.5) 45 (2.3) – 49 (7.7) 87 (1.3)
dcSSc, n (%) 10 (25) 20 (51) – – –
lcSSc, n (%) 30 (75) 19 (49) – – –
ACA, n (%) 13 (33) 12 (30) 0 – –
ATA (Scl-70), n (%) 8 (20) 2 (5) 1 – –
ARA (RNApol), n (%) 6 (15) 12 (30) 7 – –
AFA (U3RNP), n (%) 0 3 (8) 2 – –
Other ANA, n (%) 13 (33) 11 (27) 4 – –
Data are shown as the mean (S.E.M.) or number (percentage within study subgroup). eGFR: estimated glomerular filtration
rate; RNApol: anti-RNA polymerase antibody; SRC: scleroderma renal crisis; U3RNP: anti-fibrillarin autoantibody; ATA: anti-
topoisomerase.
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In more selected cases, such as those recruited into the
scleroderma lung study, there was a correlation between
the change in MCP1 and the treatment response [32].
Likewise, cross-sectional studies have shown that in idi-
opathic pulmonary fibrosis, where organ systems other
than the lungs are more likely to be normal, there is a
strong predictive value of serum MCP1 for future dis-
ease progression [33].
Urinary analytes appear to reflect renal pathology bet-
ter, evidenced by average levels being greater for SSc–
TABLE 2 Summary of analytes with ANOVA and pairwise comparison for serum








P-value P-value P-value P-value
IL6
Median 0 0.57 1.7 1.2 0.3748 0.5614 0.3041 0.133
Minimum 0 0 0 0
Maximum 5.1 3.8 11 8.2
Mean 1.3 1.1 2.7 2.1
S.D. 2 1.2 3.1 2.5
MCP1
Median 35 30 53 106 0.0001 0.0015 0.0236 0.2854
Minimum 3.4 2.5 3.4 5.1
Maximum 166 66 207 263
Mean 53 31 66 118
S.D. 53 21 49 76
TNF-a
Median 0.36 0.65 1.1 1.5 0.0196 0.1393 0.2136 0.2231
Minimum 0 0 0 0
Maximum 1.7 1.5 3.1 5
Mean 0.54 0.56 1.1 1.5
S.D. 0.6 0.47 0.98 1.2
VEGF
Median 1.6 9.9 15 32 <0.0001 0.001 0.0963 0.1453
Minimum 0 0 0 1
Maximum 60 19 74 131
Mean 13 9.1 20 43
S.D. 19 8.3 18 34
MCP3
Median 0 0 0 0 NA
Minimum 0 0 0 0
Maximum 0 0 0.45 0
Mean 0 0 0.019 0
S.D. 0 0 0.092 0
IL18
Median 6.6 3.2 17 20 0.0002 0.3991 0.0016 0.0299
Minimum 0 1.5 0 0.72
Maximum 31 8 60 60
Mean 9.2 3.7 21 23
S.D. 9.8 2.2 18 14
ICAM-1
Median 16 083 14 762 23 082 23 412 0.0004 0.413 0.0067 0.0079
Minimum 2030 10 564 4453 9580
Maximum 21 329 17 534 40 541 56872
Mean 14 287 14 321 22 118 25 449
S.D. 6055 2554 9090 11 316
VCAM-1
Median 17 561 10 749 27 047 22 538 0.0113 0.0832 0.0028 0.1945
Minimum 7436 4373 4167 1196
Maximum 48 673 25 272 58 652 51 776
Mean 22 427 13 609 28 734 23 291
S.D. 14 297 7021 14 814 11 645
CKD: chronic kidney disease; HC: healthy control; MCP1: monocyte chemoattractant protein 1; MCP2: monocyte chemoat-
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CKD than for SSc–no CKD in six of the eight analytes
examined. Although several of the proteins that were in-
creased in SSc–CKD are of interest in SSc pathogene-
sis, the overall goal of the present study was to identify
the most promising markers in the urine that could
reflect CKD in SSc and be used as future biomarkers in
observational cohort studies or interventional trials. As
outlined in the Results section, we have selected
MCP1:creatinine and ICAM-1:creatinine as the most
promising candidate markers to take forward, because
TABLE 3 Summary of analytes with ANOVA and pairwise comparison for urine














Median 0.22 0.65 0.52 0.42 0.008 0.2243 0.7273 0.0018
Minimum 0.11 0.24 0.048 0.082
Maximum 0.46 1.9 1.5 1.3
Mean 0.23 0.69 0.57 0.47
S.D. 0.1 0.51 0.36 0.3
MCP1
Median 9.8 23 23 19 0.0032 0.0868 0.5803 <0.0001
Minimum 2.2 5.9 0.81 2.1
Maximum 12 54 70 54
Mean 8.7 26 30 22
S.D. 3.4 21 20 15
TNF-a
Median 0.15 0.4 0.38 0.38 0.0164 >0.9999 0.7162 0.004
Minimum 0.016 0.18 0.028 0.018
Maximum 0.49 0.84 1.5 1.3
Mean 0.17 0.44 0.44 0.43
S.D. 0.16 0.21 0.34 0.3
VEGF
Median 31 29 34 36 0.9828 0.9081 0.7654 0.739
Minimum 17 19 11 1.8
Maximum 52 61 90 129
Mean 33 34 38 39
S.D. 10 14 19 27
MCP3
Median 0.84 1.6 3 2 0.0101 0.4744 0.2185 0.0008
Minimum 0 0.55 0 0
Maximum 2.1 3.6 10 9
Mean 0.94 1.9 3.5 3
S.D. 0.64 0.95 3 2.6
IL18
Median 3.9 5.7 8.9 7.9 0.0053 0.6337 0.0493 0.0026
Minimum 1.6 2.4 1.1 1.2
Maximum 7.4 12 31 29
Mean 2.2 2.9 7.1 6.8
S.D. 0.65 0.97 1.2 1.1
ICAM-1
Median 60 855 968 570 <0.0001 0.0134 0.7049 <0.0001
Minimum 8.8 73 9 13
Maximum 275 3991 4678 2391
Mean 94 1307 1499 807
S.D. 82 1211 1302 704
VCAM-1
Median 382 336 491 342 0.4377 0.2239 0.198 0.2928
Minimum 44 40 5.2 8.1
Maximum 735 857 2371 1435
Mean 400 387 704 509
S.D. 207 294 632 450
CKD: chronic kidney disease; HC: healthy control; MCP1: monocyte chemoattractant protein 1; MCP2: monocyte chemoat-
tractant protein 2; VCAM-1: vascular cell adhesion molecule 1; ICAM-1: intercellular adhesion molecule 1.
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they show the most significant difference across all
groups, the highest discrimination from healthy controls
and the most potential to differentiate SSc–CKD from
other causes of CKD.
There have been reports of correlation of ICAM-1 with
skin or lung involvement in SSc although, as confirmed
by the serum results in the present study, the relationship
to renal involvement compared with other adhesion mole-
cules is less clear [27]. Nevertheless, ICAM-1 has been
shown to change over time in some interventional stud-
ies, supporting its possible value as a molecular surro-
gate of the disease process [34]. Although we report the
first study of urinary ICAM-1 in SSc, there have been sev-
eral studies of urinary ICAM-1 in SLE that show elevated
levels compared with controls [34]. Although there is an
association with the presence of renal involvement in
SLE, a recent meta-analysis concluded that the current
evidence does not support urinary ICAM-1 as an effective
marker of lupus nephritis activity [35].
This is also the first study to investigate concentra-
tions of MCP1 in the urine of patients with SSc. The
SSc–CKD group had lower serum and higher urinary
concentrations of MCP1 than the SSc–no CKD group.
The negative correlation with GFR and histology studies
support the proposition that this relates to local chemo-
kine expression in the kidney [36].
MCP1 is a C-C group chemokine produced by many
cell types, including endothelial and epithelial cells and
fibroblasts [37], but monocytes/macrophages are the
major source [38]. MCP1 has been shown in previous
work to promote the differentiation of fibroblasts into
myofibroblasts in SSc via its receptor, CCR2 [39]. It is
also a chemoattractant for monocytes, T lymphocytes
and NK cells [38]. MCP1 has previously been demon-
strated to be upregulated in affected areas of SSc skin
[39], in bronchoalveolar lavage fluid [39] and in the sera
of some SSc patient subgroups [21]. Thus, MCP1 has a
plausible role in the pathogenesis or maintenance of or-
gan complications of SSc.
However, attempts to establish the serum MCP1 con-
centration as a dynamic biomarker of disease have not
been successful. One plausible explanation for this is
that serum concentrations do not reflect local tissue ex-
pression of pathogenic chemokines except where there
is a high burden of skin disease [39]. For this reason,
the identification of urine as a biomarker fluid that allows
assessment of local expression of MCP1 or other patho-
genic mediators is a potentially significant development
in the management of SSc.
Consistent with our findings in CKD, there is evidence
from juvenile onset SLE that active renal involvement is
associated with increased urinary levels of MCP1 and
that levels in SLE are higher than those in matched
healthy controls [22, 23, 40]. In adult SLE, a combined
assessment of urinary MCP1 and urinary TNF related
weak inducer of apoptosis (TWEAK) has been proposed
as an early marker of nephritis, raising the possibility of
combining urinary markers to improve performance in
FIG. 1 Candidate markers in SSc-associated chronic kidney disease and controls: serum analysis
The panels show the distribution for each analyte in serum for the controls and for patients with SSc with chronic kid-
ney disease (CKD) and those without CKD. The panels also show values for the non-SSc cohort with CKD.
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FIG. 2 Urinary analyte:creatinine ratio for candidate markers in SSc-associated chronic kidney disease and controls
The panels show the distribution for each analyte (analyte:creatinine ratio) for the controls, and for patients with SSc
with chronic kidney disease (CKD) and those without CKD. The panels also show values for the non-SSc cohort with
CKD. Significant differences by ANOVA and pairwise comparison are detailed in the main text and in Table 3.
FIG. 3 Relationship of candidate urinary markers of SSc-associated chronic kidney disease with renal function
The panels show the relationship between renal function estimated by serum creatinine or eGFR compared with uri-
nary MCP1:creatinine and urinary ICAM-1:creatinine ratio. The correlation coefficient (R) and P-value are annotated
for each analysis. eGFR: estimated glomerular filtration rate; MCP1: monocyte chemoattractant protein 1; ICAM-1:
intercellular adhesion molecule 1.
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detecting a preclinical disease state [41]. This is consis-
tent with recent results that increased urinary MCP1 might
precede and predict drug-induced renal toxicity [42].
A particular strength of our study is the inclusion and
careful stratification of three control groups: SSc–no
CKD, CKD–no SSc and healthy controls. The CKD–no
SSC controls were selected to have non-proteinuric un-
derlying diseases in order that these could serve as con-
trols for reduced GFR without the confounding of non-
selective glomerular protein leak.
Limitations include the small number of samples
and the cross-sectional design. This reflects the rela-
tive rarity of SSc and the need for well-characterized
patients in discovery studies looking for new potential
molecular markers of disease. Nevertheless, we con-
sider that the number of cases was sufficient to in-
clude most of the major patterns and subsets of SSc
as evidenced by the serological and clinical features
of our study cohort.
Another limitation is the categorization of cases of
SSc as SSc–CKD, because this inevitably includes a
wide range of severity of renal involvement and multiple
potential mechanisms of renal disease. This might ex-
plain the diversity of results for some analytes, including
MCP1. It is possible that a threshold level might be im-
portant, and future studies could compare cases with
high- and low-level urinary MCP1 to explore clinical
associations with biomarker expression.
Future work is needed to validate our cross-
sectional study and could explore the use of urinary
MCP1 and ICAM-1 as longitudinal markers. Such
studies could be in observational cohorts and could
also examine these new molecular markers in pro-
spective interventional clinical trials. These analytes
might act as pharmacodynamic markers or provide
evidence of effect on relevant pathobiology in SSc
and especially SSc–CKD.
A similar approach has been fruitful in SSc for serum IL6
and lung function decline, in idiopathic pulmonary fibrosis
with serum MCP1 predicting respiratory outcome, and in
SSc-associated pulmonary arterial hypertension (PAH),
where MCP1 showed relevant changes after treatment
[21]. Likewise, serum ICAM-1 has shown response to ex-
perimental treatment in liver disease [43].
In summary, we have taken a new approach to iden-
tify potential urinary protein markers of SSc–CKD. Two
promising candidates have been identified, and these
should be validated in future cross-sectional and longi-
tudinal studies.
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